By Sheri Kasprzak
Atlanta, Oct. 28 - CardioGenesis Corp. wrapped up a $6 million convertible financing with Laurus Master Fund Ltd., the company said Thursday.
The three-year convertible note bears an interest rate of Prime rate plus 200 basis points and is convertible into common shares at $0.50 per share.
Laurus also received warrants to buy 2.64 million shares.
CardioGenesis is a Foothill Ranch, Calif.-based medical device company specializing in cardiac disease treatment. It plans to use the funds raised in the financing with Laurus to launch its angina-relieving Transmyocardial Revascularization business and to fund research and development.
| Issuer: | CardioGenesis Corp.
|
| Issue: | Convertible notes
|
| Amount: | $6 million
|
| Maturity: | Three years
|
| Coupon: | Prime plus 200 basis points
|
| Price: | Par
|
| Conversion price: | $0.50
|
| Warrants: | For 2.64 million shares
|
| Investors: | Laurus Master Fund Ltd.
|
| Pricing date: | Oct. 26
|
| Settlement date: | Oct. 27
|
| Stock price: | $0.505 at close Oct. 28
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
